Updating results

668 results

Sort: Relevance | Date

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery (ID1105)

Proposed [GID-TA10348] Expected publication date: TBC

Technology appraisal guidance Proposed

Water borne infections

Proposed [GID-QS10125] Expected publication date: TBC

Quality standard Proposed

Vulnerable populations: strategies for tackling inequalities

Proposed [GID-QS10124] Expected publication date: TBC

Quality standard Proposed

Transport and health

Proposed [GID-QS10123] Expected publication date: TBC

Quality standard Proposed

Programme management: effective ways to run public health programmes to generate a change in behaviour

Proposed [GID-QS10122] Expected publication date: TBC

Quality standard Proposed

Gambling

Proposed [GID-QS10099] Expected publication date: TBC

Quality standard Proposed

Natural environments

Proposed [GID-QS10119] Expected publication date: TBC

Quality standard Proposed

Heat wave planning

Proposed [GID-QS10116] Expected publication date: TBC

Quality standard Proposed

Mental well-being: life course, settings and subgroups

Proposed [GID-QS10118] Expected publication date: TBC

Quality standard Proposed

Spatial planning

Proposed [GID-QS10112] Expected publication date: TBC

Quality standard Proposed

Road safety

Proposed [GID-QS10111] Expected publication date: TBC

Quality standard Proposed

Non-antibiotic clinical management of infectious diseases

Proposed [GID-QS10120] Expected publication date: TBC

Quality standard Proposed

Prevention of dementia

Proposed [GID-QS10109] Expected publication date: TBC

Quality standard Proposed

Secondary care management of malignant hypertension

Proposed [GID-QS10107] Expected publication date: TBC

Quality standard Proposed

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

Proposed [GID-QS10106] Expected publication date: TBC

Quality standard Proposed

Gout

Proposed [GID-QS10100] Expected publication date: TBC

Quality standard Proposed

Blood transfusion in neonatology

Proposed [GID-QS10098] Expected publication date: TBC

Quality standard Proposed

Readmission to ICU within 48hrs

Proposed [GID-QS10105] Expected publication date: TBC

Quality standard Proposed

Nutrition in hospital

Proposed [GID-QS10104] Expected publication date: TBC

Quality standard Proposed

Managing symptoms with an uncertain cause

Proposed [GID-QS10103] Expected publication date: TBC

Quality standard Proposed

Shared decision-making: practical guidance for health and social care professionals

Proposed [GID-QS10097] Expected publication date: TBC

Quality standard Proposed

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

Proposed [GID-TA10390] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treatment-resistant depression (ID1414)

Proposed [GID-TA10371] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Highly specialised technologies guidance Proposed

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Housing: planning to improve health and wellbeing

Proposed [GID-QS10117] Expected publication date: TBC

Quality standard Proposed

Hepatitis C

Proposed [GID-QS10126] Expected publication date: TBC

Quality standard Proposed

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

Proposed [GID-TA10389] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Pitolisant hydrochloride for treating obstructive sleep apnoea ID1065

Proposed [GID-TA10385] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Proposed [GID-TA10458] Expected publication date: TBC

Technology appraisal guidance Proposed

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

Proposed [GID-TA10457] Expected publication date: TBC

Technology appraisal guidance Proposed

Brolucizumab for treating wet age-related macular degeneration [ID1254]

Proposed [GID-TA10455] Expected publication date: TBC

Technology appraisal guidance Proposed

Galcanezumab for preventing migraine [ID1372]

Proposed [GID-TA10454] Expected publication date: TBC

Technology appraisal guidance Proposed

Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

Proposed [GID-TA10470] Expected publication date: TBC

Technology appraisal guidance Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Technology appraisal guidance Proposed

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Technology appraisal guidance Proposed

Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

Proposed [GID-TA10524] Expected publication date: 26 June 2020

Technology appraisal guidance Proposed

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

Proposed [GID-TA10526] Expected publication date: TBC

Technology appraisal guidance Proposed

Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

Proposed [GID-TA10387] Expected publication date: TBC

Technology appraisal guidance Proposed

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Proposed [GID-TA10451] Expected publication date: 10 June 2020

Technology appraisal guidance Proposed

Zynteglo for treating transfusion-dependent beta-thalassaemia ID968

Proposed [GID-TA10334] Expected publication date: 24 June 2020

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed